Seres Therapeutics Soars 45.66% on Nestlé Acquisition Rumors

On September 8, 2025, Seres Therapeutics experienced a significant surge, rising 45.66% in pre-market trading. This substantial increase has drawn attention to the company, which specializes in developing microbiome therapeutics.

Seres Therapeutics, Inc. is a leading player in the microbiome therapeutics sector, focusing on the development of biological drugs. The company's innovative approach to leveraging the microbiome for therapeutic purposes has positioned it as a key player in the biotechnology industry.

Recent reports indicate that Nestlé is exploring the possibility of acquiring Seres Therapeutics. This potential acquisition has sparked interest in the market, as it could significantly impact the company's future trajectory and strategic direction. The discussions reportedly include the potential for Nestlé to integrate Seres Therapeutics' microbiome technologies into its own portfolio, enhancing its capabilities in the health and wellness sector.